Upcoming Webinar
Repotrectinib (Augtyro®) in Patients with ROS1 Fusion-Positive NSCLC: Data from the Pivotal Phase 1/2 TRIDENT-1 Trial
Date: December 4, 2025 | 2:00 PM
When: Thursday, December 4 | 2 p.m. EST
Presenters: Magda Dankowska, PharmD, BCOP | Bristol Myers Squibb
Repotrectinib is quickly becoming a key consideration for patients with ROS1 fusion–positive NSCLC—and the TRIDENT-1 trial offers some of the clearest evidence yet on where it may fit in practice.
Magda Dankowska will take a clinically focused look at this next-generation TKI and what the data means for real-world treatment decisions.
Learn about:
- The mechanism of action behind repotrectinib and its clinical rationale
- Efficacy and safety outcomes from the pivotal Phase 1/2 TRIDENT-1 trial
- How repotrectinib’s clinical profile compares with other ROS1-targeted options
- Practical implications for sequencing and patient selection in oncology care
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
Repotrectinib (Augtyro®) in Patients with ROS1 Fusion-Positive NSCLC: Data from the Pivotal Phase 1/2 TRIDENT-1 Trial
December 4, 2025 | 2:00 PM







